Announcements Trials
Browse Landscape

Status

No longer available 2

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Recurrence 1

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × Expanded_access × Panobinostat × Clear all
NCT02568943 2020-04-08

An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

Novartis

No longer available
Plasma cell

Multiple Myeloma, Recurrence

NCT02204553 2016-01-05

Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

Novartis

No longer available
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡